CO2021003412A2 - Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables - Google Patents

Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables

Info

Publication number
CO2021003412A2
CO2021003412A2 CONC2021/0003412A CO2021003412A CO2021003412A2 CO 2021003412 A2 CO2021003412 A2 CO 2021003412A2 CO 2021003412 A CO2021003412 A CO 2021003412A CO 2021003412 A2 CO2021003412 A2 CO 2021003412A2
Authority
CO
Colombia
Prior art keywords
pharmaceutically acceptable
acceptable salts
thiazole derivatives
new thiazole
new
Prior art date
Application number
CONC2021/0003412A
Other languages
English (en)
Inventor
Kwang Ok Lee
Jakyung Yoo
Jun Hee Lee
Mijung Lee
Kangwoo Lee
Jieun Min
Original Assignee
Yungjin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yungjin Pharmaceutical Co Ltd filed Critical Yungjin Pharmaceutical Co Ltd
Publication of CO2021003412A2 publication Critical patent/CO2021003412A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

El presente invento proporciona un nuevo derivado de tiazol o una sal farmacéuticamente aceptable de éste y un método para prepararlo. El derivado de tiazol o una sal farmacéuticamente aceptable de éste, de acuerdo con el presente invento, tiene una actividad inhibidora selectiva contra la quinasa dependiente de ciclina (CDK) y, por lo tanto, puede usarse de manera útil como un agente preventivo o terapéutico para diversas enfermedades asociadas con la CDK.
CONC2021/0003412A 2018-09-17 2021-03-16 Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables CO2021003412A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180111001 2018-09-17
PCT/KR2019/011887 WO2020060112A1 (en) 2018-09-17 2019-09-11 Novel thiazole derivatives and pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
CO2021003412A2 true CO2021003412A2 (es) 2021-04-08

Family

ID=69887568

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0003412A CO2021003412A2 (es) 2018-09-17 2021-03-16 Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables

Country Status (19)

Country Link
US (1) US12110299B2 (es)
EP (1) EP3853225B1 (es)
JP (1) JP7235859B2 (es)
KR (2) KR102130253B1 (es)
CN (1) CN112739695A (es)
AU (1) AU2019344240B2 (es)
BR (1) BR112021004999A2 (es)
CA (1) CA3106855A1 (es)
CL (1) CL2021000594A1 (es)
CO (1) CO2021003412A2 (es)
EA (1) EA202190558A1 (es)
IL (1) IL280639B (es)
MX (1) MX2021002456A (es)
PH (1) PH12021550572A1 (es)
SG (1) SG11202100531RA (es)
TW (1) TW202023548A (es)
UA (1) UA125427C2 (es)
WO (1) WO2020060112A1 (es)
ZA (1) ZA202101652B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3853225B1 (en) 2018-09-17 2023-11-29 Yungjin Pharm. Co., Ltd. N-(5-(3-(1-((thiazol-2-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide derivatives as cdk7 inhibitors for the treatment of cancer
WO2021182914A1 (ko) * 2020-03-13 2021-09-16 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259341A (en) 1977-06-01 1981-03-31 Merck & Co., Inc. Di- and tri-substituted thiazoles
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP1087951B9 (en) 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
WO2000004926A2 (en) 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
DE60216097T2 (de) * 2001-07-19 2007-06-28 Pfizer Italia S.R.L. Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel
DK1700856T3 (en) 2003-12-26 2015-12-14 Kyowa Hakko Kirin Co Ltd thiazole
MX2007001846A (es) * 2004-08-17 2007-03-28 Hoffmann La Roche Hidantoinas sustituidas.
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US20090264415A2 (en) * 2004-12-30 2009-10-22 Steven De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
US20090105250A1 (en) 2005-01-26 2009-04-23 Irm Llc Compounds and compositions as protein kinase inhibitors
US8183239B2 (en) 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
AU2007299870A1 (en) 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2155166A2 (en) 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
US20100249402A1 (en) 2007-07-27 2010-09-30 Dong Wha Pharmaceutical Co. Ltd. Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition for preventing or treating osteporosis comprising the same
ES2331220B1 (es) 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
US20110263564A1 (en) * 2008-10-29 2011-10-27 Sirtris Pharmaceuticals, Inc. Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
US9221773B2 (en) 2009-12-22 2015-12-29 The Translational Genomics Research Institute Benzamide derivatives
WO2011084985A1 (en) * 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
US8404859B2 (en) 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
WO2012161879A1 (en) 2011-05-23 2012-11-29 Merck Patent Gmbh Thiazole derivatives
WO2013146754A1 (ja) 2012-03-27 2013-10-03 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
TW201443023A (zh) 2013-01-18 2014-11-16 必治妥美雅史谷比公司 作爲ｒｏｃｋ抑制劑之酞□酮及異喹啉酮
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
US10106526B2 (en) 2014-04-04 2018-10-23 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
GB201417561D0 (en) 2014-10-03 2014-11-19 Redx Pharma Ltd Compounds
KR20160118417A (ko) 2015-04-01 2016-10-12 (주)황후연 살모사 뱀독 액상 혼합물의 아토피 화장품 및 연고의 원료 조성물 및 그 제조 방법
AU2016272900A1 (en) 2015-06-04 2017-12-07 Novartis Ag Use of IL-1 beta binding antibodies to treat peripheral arterial disease
MY190459A (en) * 2015-06-04 2022-04-21 Aurigene Discovery Tech Ltd Substituted heterocyclyl derivatives as cdk inhibitors
KR101802514B1 (ko) 2016-12-09 2017-11-29 아주대학교산학협력단 Ｎｍ를 포함하는 염증성 질환의 예방 또는 치료용 조성물
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
EP3853225B1 (en) 2018-09-17 2023-11-29 Yungjin Pharm. Co., Ltd. N-(5-(3-(1-((thiazol-2-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide derivatives as cdk7 inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
IL280639B (en) 2022-07-01
EP3853225A4 (en) 2022-06-15
CA3106855A1 (en) 2020-03-26
ZA202101652B (en) 2022-07-27
US12110299B2 (en) 2024-10-08
JP2021535924A (ja) 2021-12-23
AU2019344240A1 (en) 2021-02-25
PH12021550572A1 (en) 2021-10-25
KR102130253B1 (ko) 2020-07-03
AU2019344240B2 (en) 2022-09-29
UA125427C2 (uk) 2022-03-02
CN112739695A (zh) 2021-04-30
EP3853225C0 (en) 2023-11-29
EP3853225B1 (en) 2023-11-29
EA202190558A1 (ru) 2022-02-03
CL2021000594A1 (es) 2021-12-03
IL280639A (en) 2021-03-25
JP7235859B2 (ja) 2023-03-08
US20210284658A1 (en) 2021-09-16
BR112021004999A2 (pt) 2021-06-08
EP3853225A1 (en) 2021-07-28
WO2020060112A1 (en) 2020-03-26
SG11202100531RA (en) 2021-02-25
KR20200032002A (ko) 2020-03-25
TW202023548A (zh) 2020-07-01
MX2021002456A (es) 2021-06-15
KR20200078465A (ko) 2020-07-01

Similar Documents

Publication Publication Date Title
CO2019008487A2 (es) Compuesto de quinazolina
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
MX2018013387A (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas.
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
DOP2021000111A (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
BR112018016729A2 (pt) novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase
CO2021003412A2 (es) Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
SV2016005313A (es) Derivados de carboxamida
DOP2012000058A (es) Agente terapeutico para trastornos del estado de animo
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CO2020000374A2 (es) Proceso mejorado para preparar derivados de aminopirimidina
CO2019012125A2 (es) Inhibidores ip6k
UY36123A (es) Derivados de carboxamida
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
DOP2012000056A (es) Agente terapeutico para trastornos de ansiedad
CL2017002229A1 (es) Inhibidores de bace1.
CO2020000595A2 (es) Intermedios novedosos útiles para la síntesis de derivados de aminopirimidina, proceso para prepararlos, y proceso para preparar derivados de aminopirimidina usando estos
CL2016002870A1 (es) Derivados bicíclicos y composición farmacéutica que incluye los mismos
CL2020000175A1 (es) Combinaciones farmacéuticas que comprenden anticuerpos contra bst1 y citadina.